Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.

Glucocorticoids may confer adverse outcomes in patients with suspected IPF

02 Apr 2018

There have been a substantial number of severe adverse events (SAE) and a faster decrease in forced vital capacity (FVC) in patients with possible idiopathic pulmonary fibrosis (posIPF) taking steroid therapy, a new study has shown.

Several prednisone-treated posIPF patients were nonresponders (68 percent), with >5-percent decline in FVC or death within 6 months from baseline. In addition, 90 percent of patients with radiographical presence of honeycombing were nonresponders.

On the other hand, six of seven patients with focal desquamative interstitial pneumonia-like reaction in surgical lung biopsy (SLB) who had stopped smoking for <5 years ago responded to prednisone, with <5-percent decrease in FVC.

In 32 patients with available FVC data, mean FVC decline was 8.7 percent (95 percent CI, 3.1–14.3 percent) and 20 percent (9.4–31.1 percent) before and after treatment, respectively. A total of 12 SAE and five deaths occurred within the first 3 months on prednisone (at dosage >0.3 mg/kg/day).

The investigators retrospectively analysed a multicentre cohort of 59 prednisone-treated posIPF patients to assess outcomes of immunomodulatory treatment. Prednisone starting dose was 0.5 mg/kg/day and tapered to 0.15 mg/day/kg over 6 months. FVC and SAE, defined as death or hospital admissions, were the outcome measures.

“The diagnostic classification of posIPF is characterized by a radiological pattern of inconsistent usual interstitial pneumonia (UIP) on high‐resolution computed tomography scan and a UIP pattern in SLB,” the investigators said.

“The evidence base to guide treatment for patients with posIPF is lacking; the clinician must choose between observation, treatment with immunomodulatory agents or antifibrotic agents,” they added.

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Rachel Soon, 28 Aug 2020
MOH Director-General Tan Sri Dato' Seri Dr Noor Hisham Abdullah speaks about NHMS 2019 and pharmacists' roles in combating NCDs among Malaysians.
Stephen Padilla, 08 Apr 2020
An antiparasitic drug approved by the Food and Drug Administration (FDA) has been found to be effective in stopping the growth of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in a laboratory experiment, according to a collaborative study.
Audrey Abella, 18 Dec 2020
Omecamtiv mecarbil (OM), an investigational selective cardiac myosin activator, may reduce the risk of heart failure (HF)-related events or cardiovascular (CV) deaths in patients with chronic HFrEF*, according to the late-breaking GALACTIC-HF** trial presented at AHA 2020.
Pearl Toh, 17 Dec 2020
A single dose of loratadine/pseudoephedrine combination tablet provides over twice as much nasal relief within an hour compared with fluticasone nasal spray in patients with allergic rhinitis, according to a head-to-head comparison study presented at ACAAI 2020 Meeting.